OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Cancer is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Deep learning in cancer pathology: a new generation of clinical biomarkers	357
The lingering mysteries of metastatic recurrence in breast cancer	314
Achieving clinical success with BET inhibitors as anti-cancer agents	234
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression	226
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance	188
Insights into the role of sialylation in cancer progression and metastasis	172
Tumour treating fields therapy for glioblastoma: current advances and future directions	166
Treatment strategies for breast cancer brain metastases	142
Mutational drivers of cancer cell migration and invasion	140
Promises and challenges of adoptive T-cell therapies for solid tumours	136
EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures	135
Cysteine metabolic circuitries: druggable targets in cancer	128
Radiomics and radiogenomics in gliomas: a contemporary update	113
The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO)	108
Artificial intelligence in oncology: current applications and future perspectives	102
Endocytosis: a pivotal pathway for regulating metastasis	96
Cell-free DNA analysis in current cancer clinical trials: a review	95
Metabolic reprogramming in prostate cancer	94
Cancer immunotherapy: it’s time to better predict patients’ response	92
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience	88
Biomarkers of response to PD-1 pathway blockade	88
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial	87
The gut microbiome: what the oncologist ought to know	85
Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview	83
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study	82

The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020	80
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma	77
Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects	76
Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer	74
Tumour-infiltrating lymphocytes: from prognosis to treatment selection	73
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy	73
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma	71
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	71
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours	71
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours	71
Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project	68
Cannabinoids as anticancer drugs: current status of preclinical research	65
Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)	65
Long non-coding RNAs are involved in alternative splicing and promote cancer progression	65
Roles of mitochondria in the hallmarks of metastasis	64
Cancer cachexia: a nutritional or a systemic inflammatory syndrome?	64
The current treatment landscape in the UK for stage III NSCLC	64
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	64
The current status of risk-stratified breast screening	64
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges	63
Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma	62
Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations	61
Overcoming the challenges associated with CD3+ T-cell redirection in cancer	60
Vascular normalisation as the stepping stone into tumour microenvironment transformation	59
Non-coding RNAs as liquid biopsy biomarkers in cancer	57
Detection of clustered circulating tumour cells in early breast cancer	57
UK Biobank: a globally important resource for cancer research	56
Cancer metastasis as a non-healing wound	56
Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies	56
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry	54